Gilead
Last updated Jun 16, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
73%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Endocrinology
- Type 2 Diabetes Mellitus
- Infectious Disease
- HIV
- Hepatology
Highest priority development: IND Application Reporting: IND Safety Reports
Regulatory precedent
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Gilead.
Competitive pressure: Low
Portfolio impact: High
Evidence coverage: 73%
Active Signals
9
Investigate Priority
1
Opportunity Score
487
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- InvestigateJun 16, 2026Score 62Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
Infectious Disease · HIV
- MonitorJun 30, 2026Score 61FDA Accepts Supplement for Trodelvy (Sacituzumab Govitecan-Hziy)
Oncology · Antibody-Drug Conjugate
- MonitorJun 27, 2026Score 54FDA Approves KEYTRUDA and Trodelvy Combination for First-Line TNBC Treatment
Oncology · Triple-Negative Breast Cancer
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- IND Application Reporting: IND Safety ReportsModerate Confidence · 83%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of DrugModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - Clinical trials for medicines: collection, verification and reporting of safety eventsModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)MHRAMHRARegunera - Drug Trials Snapshots: YARTEMLEAModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Capital Markets
SEC filings, IPO activity, and capital markets events from the Business Intelligence Layer.
No capital markets intelligence is available yet.
Financing History
Venture funding, follow-on offerings, PIPE financings, and debt financing.
No financing history is available yet.
Licensing & Partnerships
Licensing agreements, strategic partnerships, and distribution deals.
No licensing or partnership activity is available yet.
M&A Activity
Acquisitions, mergers, and divestitures.
No M&A activity is available yet.
Investor Activity
Earnings releases, investor presentations, and conference appearances.
No investor activity is available yet.
Executive Changes
CEO appointments, board changes, and leadership restructuring.
No executive changes are available yet.
Business Timeline
Chronological business intelligence events across financing, licensing, M&A, and commercial strategy.
No business timeline events are available yet.
Strategic Signals
Higher-order strategic intelligence fused from regulatory, scientific, business, and competitive events. Signals answer what it means — not just what happened.
Strategic signals will appear once sufficient event convergence is detected.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
- InvestigateScore 62Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
Infectious Disease · HIV
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Gilead right now?
- Which regulatory precedents should Gilead monitor in Endocrinology and Type 2 Diabetes Mellitus?
- Which pipeline programs should Gilead prioritize for competitive review?
- What signals require immediate investigation for Gilead?
- Summarize the strategic implications of recent developments for Gilead.
- Where is the greatest uncertainty in Gilead's competitive positioning?